Equities Analysts Set Expectations for CervoMed Q1 Earnings

CervoMed Inc. (NASDAQ:CRVO) – Investment analysts at Roth Capital upped their Q1 2025 earnings per share (EPS) estimates for shares of CervoMed in a report issued on Tuesday, December 10th. Roth Capital analyst B. Pachaiyappan now expects that the company will post earnings of ($0.52) per share for the quarter, up from their prior estimate of ($0.53). Roth Capital currently has a “Strong-Buy” rating on the stock. The consensus estimate for CervoMed’s current full-year earnings is ($1.76) per share. Roth Capital also issued estimates for CervoMed’s Q2 2025 earnings at ($0.44) EPS, Q3 2025 earnings at ($0.35) EPS, Q4 2025 earnings at ($0.27) EPS and FY2025 earnings at ($1.57) EPS.

CervoMed (NASDAQ:CRVO) last released its earnings results on Tuesday, November 12th. The company reported ($0.55) earnings per share for the quarter, missing the consensus estimate of ($0.41) by ($0.14). CervoMed had a negative net margin of 118.68% and a negative return on equity of 44.11%. The business had revenue of $1.94 million for the quarter, compared to the consensus estimate of $1.75 million.

A number of other brokerages also recently commented on CRVO. Chardan Capital restated a “neutral” rating on shares of CervoMed in a research note on Wednesday. Morgan Stanley restated an “underweight” rating on shares of CervoMed in a research note on Wednesday. Canaccord Genuity Group dropped their target price on CervoMed from $65.00 to $12.00 and set a “buy” rating on the stock in a research report on Wednesday. Brookline Capital Management downgraded shares of CervoMed from a “strong-buy” rating to a “hold” rating in a report on Tuesday. Finally, HC Wainwright began coverage on shares of CervoMed in a report on Thursday, December 5th. They issued a “buy” rating and a $42.00 price objective on the stock. One investment analyst has rated the stock with a sell rating, three have assigned a hold rating, four have given a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $42.00.

CervoMed Stock Down 1.6 %

Shares of NASDAQ:CRVO opened at $1.90 on Friday. CervoMed has a fifty-two week low of $1.81 and a fifty-two week high of $26.38. The firm has a 50-day simple moving average of $11.28 and a 200 day simple moving average of $14.67.

Hedge Funds Weigh In On CervoMed

Several large investors have recently bought and sold shares of CRVO. Geode Capital Management LLC grew its stake in shares of CervoMed by 13.9% in the 3rd quarter. Geode Capital Management LLC now owns 114,934 shares of the company’s stock worth $1,678,000 after purchasing an additional 14,042 shares during the last quarter. State Street Corp increased its stake in CervoMed by 28.1% in the 3rd quarter. State Street Corp now owns 104,456 shares of the company’s stock valued at $1,525,000 after buying an additional 22,903 shares during the period. Renaissance Technologies LLC raised its holdings in shares of CervoMed by 5.2% during the second quarter. Renaissance Technologies LLC now owns 32,333 shares of the company’s stock worth $554,000 after acquiring an additional 1,600 shares in the last quarter. Citizens Financial Group Inc. RI raised its stake in shares of CervoMed by 13.2% during the 3rd quarter. Citizens Financial Group Inc. RI now owns 30,509 shares of the company’s stock worth $445,000 after purchasing an additional 3,553 shares in the last quarter. Finally, Bank of New York Mellon Corp bought a new position in CervoMed during the second quarter valued at approximately $236,000. Institutional investors and hedge funds own 25.15% of the company’s stock.

About CervoMed

CervoMed Inc, a biotechnology company, engages in the development and commercialization of treatments for age-related neurologic disorders. Its lead drug candidate is neflamapimod, an orally administered small molecule brain penetrant for the treatment of dementia with Lewy bodies (DLB), Alzheimer's diseases, frontotemporal dementia, and ischemic stroke recovery.